ALEXANDRIA, Va., July 1, 2025 /PRNewswire/ -- Today, the National Center for Missing & Exploited Children (NCMEC), in partnership with GSTV, is launching a powerful nationwide campaign to help find Kevin Verville Jr., who was abducted as an infant from Oceanside, California in 1980.
jwplayer.key="3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE="
NCMEC_Missing_child_Kevin_Verville jwplayer('myplayer1').setup({file: 'https://mma.prnasia.com/media2/2722326/NCMEC_Missing_child_Kevin_Verville.mp4', image: 'https://mma.prnasia.com/media2/2722326/NCMEC_Missing_child_Kevin_Verville.mp4?p=thumbnail', autostart:'false', stretching : 'uniform', width: '512', height: '288'});
From July 1 through July 31, a newly released age-progression image of Kevin—created by a forensic artist at NCMEC to show what he might look like today—will be broadcast coast to coast.
Recognizing the urgent need to reach a broad, national audience in Kevin's case, GSTV—the national digital video network viewed at more than 29,000 fuel retailers across 49 states—is generously donating screen time across its network to highlight Kevin's story throughout the month of July. This collaboration allows NCMEC to engage viewers across the country, dramatically increasing the chances that someone will recognize Kevin and come forward with information.
Kevin was abducted on July 1, 1980, when investigators say an unknown woman approached the Verville family at their apartment, an off-base military housing complex home near Camp Pendleton. The woman called herself, "Sheila," and claimed to be from an organization helping young military families. She drove Kevin and his mother to her office and at some point, convinced Kevin's mom to get out of the car. The unknown woman sped off with baby Kevin who was just 17 days old. Read more about Kevin's story on NCMEC's blog.
"Kevin's family has endured 45 years of unimaginable pain, believing his case was forgotten. Now, with national attention, there's real hope for answers," said Angeline Hartmann, director of Communications at NCMEC. "We believe Kevin is still out there, likely living under another name, unaware he was kidnapped as a baby. He could be anywhere in the country, so it's critical to reach as many people as possible."
NCMEC and GSTV have worked together since 2019 to feature missing children on screens across the country. In addition to this nationwide initiative, every month GSTV gives NCMEC space on screens in 25 states to feature the cases of missing children.
"It's beyond heartbreaking for a family to live with not knowing what has happened to their child," said Violeta Ivezaj, senior vice president of Business Operations at GSTV. "We've seen the power of GSTV's partnership with NCMEC to help reunite missing children with their families in individual states and markets, and we hope that the focused national attention for this case will also help to bring some resolution to Kevin's family."
A full list of participating fuel retailers can be found at gstv.com/missingkids.
Anyone with information about Kevin's case is urged to call NCMEC at 1-800-THE-LOST (1-800-843-5678).
GSTV does not operate in New Jersey
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
NCMEC and GSTV Go National to Help Solve Baby Kidnapping Case
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
